目的 探讨益心舒胶囊联合盐酸胺碘酮片治疗非瓣膜性心房颤动的疗效。方法 选取2023年6月—2024年8月在石家庄市第三医院就诊的共计102例非瓣膜性心房颤动患者，按照随机数字表法将所有患者分为对照组和治疗组，每组各51例。对照组口服盐酸胺碘酮片，1片/次，3次/d。治疗组在对照组基础上口服益心舒胶囊，3次/d,3粒/次。两组的疗程为2个月。比较两组患者的治疗效果、房颤症状、心功能指标和血清指标水平。结果 治疗组的总有效率明显比对照组高，组间比较差异显著（96.08%vs 84.31%,P<0.05）。治疗后，两组的心房颤动发作频率和持续时间均减少（P<0.05），且治疗组心房颤动发作频率和持续时间低于对照组（P<0.05）。治疗后，两组的左房射血分数（LAEF）、左心耳排空速度（VLAA）均升高，左房容积指数（LAVI）均降低（P<0.05）；治疗组的LAEF、VLAA高于对照组，LAVI低于对照组（P<0.05）。治疗后，两组的血清血管细胞黏附分子1(VCAM-1)、高迁移率族蛋白B1(HMGB-1)、内皮素-1(ET-1)水平均降低P<0.05），治疗组的血清VCAM-1、HMGB-1、ET-1水平均低于对照组（P<0.05）。结论 益心舒胶囊联合盐酸胺碘酮片可提高非瓣膜性心房颤动的临床疗效，显著减轻心房颤动症状，改善心功能，减轻血管内皮功能。

Objective To investigate the clinical efficacy of Yixinshu Capsules combined with Amiodarone Hydrochloride Tablets in treatment of non valvular atrial fibrillation. Methods A total of 102 patients with non valvular atrial fibrillation who visited The Third Hospital of Shijiazhuang from June 2023 to August 2024 were divided into control group and treatment group according to the random number table method, with 51 cases in each group. Patients in the control group took Amiodarone Hydrochloride Tablets orally, 1 tablets/time, 3 times daily. Patients in the treatment group were po administered with Yixinshu Capsules on the basis of the control group, 3 times daily, 3 capsules/time. The course for two groups was 2 months. The treatment efficacy, atrial fibrillation symptoms, cardiac function indicators, and serum indicator levels between two groups of patients were compared. Results The total effective rate of the treatment group was significantly higher than that of the control group, and the difference between the groups was significant（96.08% vs 84.31%, P＜0.05）. After treatment, the frequency and duration of atrial fibrillation in two groups were decreased（P＜0.05）, and the frequency and duration of atrial fibrillation in the treatment group were lower than those in the control group（P＜0.05）. After treatment, LAEF and VLAA of the two groups were increased, while LAVI was decreased（P＜0.05）. LAEF and VLAA of the treatment group were higher than those of the control group, but LAVI was lower than that of the control group（P＜0.05）. After treatment, the levels of serum VCAM-1, HMGB-1, and ET-1 in two groups were decreased（P＜0.05）, and the levels of VCAM-1, HMGB-1, and ET-1 in the treatment group were lower than those in the control group（P＜0.05）. Conclusion The combination of Yixinshu Capsules and Amiodarone Hydrochloride Tablets can improve the efficacy of non valvular atrial fibrillation, significantly reduce atrial fibrillation symptoms, improve heart function, and alleviate vascular endothelial function.

R972

河北省医学科学研究课题(20241920)